Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CurePML - Allogeneic HPyV-2-specific T-cell Therapy in Patients With Progressive Multifocal Leukoencephalopathy

NCT06990087 is registered in ClinicalTrials.gov with Hannover Medical School as lead sponsor.

NCT NCT06990087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06990087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CurePML - Allogeneic HPyV-2-specific T-cell Therapy in Patients With Progressive Multifocal Leukoencephalopathy
Lead sponsor
Hannover Medical School
Phase
Phase 2
Overall status
Recruiting
Start date
February 6, 2026
Completion date
November 30, 2027
Enrollment
23 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

progressive multifocal leucoencephalopathy (pml)